Globeflex Capital L P actively adjusted its positions across several public companies in Q1, trimming Itron and IBEX while boosting stakes in Bioventus, CareDx, and Encore Capital Group. The firm reduced its Itron stake by 14.4% to about 45,491 shares, and also cut its IBEX holding by roughly half, reflecting selective repositioning in diversified tech and industrial names. Conversely, Globeflex raised its Bioventus stake by about 60% to 123,052 shares, signaling growing confidence in the medical device company. It also increased its CareDx exposure by 49.4%, expanding its position to 119,252 shares, and reduced Encore Capital Group by 14.5% to 96,072 shares, indicating varied conviction across the portfolio. Together, these moves illustrate a strategy of targeted size changes rather than uniform direction, with other hedge funds subsequently adjusting alongside Globeflex in several of the same stocks. The net effect is a more nuanced tilt within a diversified, actively managed set of holdings.